Building a Business Empire with my Technological System

Chapter 159: Shocking Reveal
With that powerful declaration opening, Bridget and Antoneitte were stunned.

”That’s a wonderful opener, Mr. Reyes. But can we get down on the business,” Antoinette said.

”Of course, Mrs. Estolas. Juliet, we will start the presentation where I will show you the current market of the pharmaceutical and medical technology industries, and then we will discuss our strategic approach and how we plan to position ourselves within these markets,” Michael explained, setting the tone for the meeting.

He waited as the projector projected the specific slide. The moment he saw it flashed on the white screen, he began.

”The pharmaceutical and medical technology sectors are experiencing significant growth. This is driven by advances in technology, an aging population, and increasing healthcare expenditures globally.”

Juliett clicked on the next slide, showing a graph of market trends.

”As you can see, there’s a steady upward trend,” Michael pointed at the graph. ”Because we know that as we age, complications arise, and the demand for medical innovations and treatments increases. This presents a substantial market opportunity for us.”

He paused, letting the information sink in before continuing. ”However, entering these markets is not without its challenges. We’re up against established players and a complex regulatory environment.”

Juliet, taking over, explained, ”Our strategy focuses on differentiation through innovation. We aim to develop unique medical technologies and pharmaceutical products that address unmet needs in the market. This will not only provide value to patients but also position us strongly against competitors.”

”Okay...and where is that technology and pharmaceutical products?” Bridget asked, looking over as if emphasizing that she was not seeing one.

”Well...” Juliet cleared his throat. ”This is the part where Mr. Reyes said that he’ll reveal it himself.”

All eyes turned to Michael.

”Of course, you are all wondering what our products will be, and luckily, I have prepared my own set of presentation materials for this,” Michael said, fetching a remote to switch the display.

He clicked through to a slide showing a list of incurable diseases from the World Health Organization (WHO) and their current treatment gaps.

”Explain your product,” Bridget chimed.

”Okay...so this pill,” Michael resumed, ”is not just any ordinary medication. It’s engineered using a nanotechnology-based delivery system. This system allows the precise targeting of neural pathways affected by Alzheimer’s disease.”

He clicked on a detailed slide illustrating the mechanism. ”The pill releases nanoparticles designed to cross the blood-brain barrier, a challenge for traditional treatments. Once inside the brain, these particles selectively bind to the amyloid plaques and tau tangles, facilitating their breakdown and removal by the body’s immune system.”

Michael noticed the intrigued looks and continued, ”This approach not only halts the progression of Alzheimer’s but potentially reverses the damage caused by the disease. It’s like sending in a highly specialized cleanup crew to restore brain function.”

He then shifted to the business side. ”From an investment perspective, this represents a groundbreaking advancement in medical science. Alzheimer’s affects millions worldwide, and the market for an effective cure is vast and untapped. We’re not just selling a pill; we’re providing a solution to one of the most pressing medical challenges of our age.”

Antoinette, now more interested, leaned forward. ”So, you’re combining high-tech engineering with medical science. But what about clinical trials, and FDA approvals? Like how can you prove that this pill of yours actually works?”

”That’s the hardest part, we may have to conduct extensive research and rigorous clinical trials to validate the efficacy and safety of our pill,” Michael acknowledged.

”And where will you find participants for it? I believe there is a process for it right?” Antoinette continued.

”Yes, there is a defined process,” Michael confirmed. ”We’ll start with preclinical trials on cellular models and then progress to animal testing to evaluate the drug’s safety profile and pharmacological effects. Once we have positive results from these stages, we’ll apply for approval to conduct human clinical trials.”

He explained further, ”For human trials, we’ll collaborate with medical research centers and hospitals to recruit participants. These will be people diagnosed with early to mid-stage Alzheimer’s, ensuring a controlled and ethical research environment.”

Michael continued to detail the phased approach they planned to take, from initial safety studies in a small group of volunteers to larger efficacy trials.

”Our goal is to rigorously test and validate the pill’s effectiveness in improving cognitive function and slowing or reversing Alzheimer’s progression.”

”I haven’t understood a thing...but what’s the other one that you have in medical technology?”

”For that, I’m going to have you all take a deep breath because what I’m about to reveal will surely shock you,” Michael paused for dramatic effect. ”For our medical technology company, let’s just say I have built a pod designed to cure cancer.”